FLUOXETINE HYDROCHLORIDE (fluoxetine hcl) by Lavipharm is unknown, it is presumed to be linked to its inhibition of cns neuronal uptake of serotonin. Approved for depression. First approved in 2011.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Fluoxetine HCl is an oral tablet formulation of fluoxetine, a selective serotonin reuptake inhibitor (SSRI) approved in 2011 for the treatment of depression. The drug works by inhibiting CNS neuronal uptake of serotonin, though its precise mechanism remains incompletely understood. It is a small-molecule therapeutic indicated as a standard antidepressant for major depressive disorder.
Product is at peak lifecycle stage with moderate competitive pressure (30/100), indicating a stable but mature commercial environment with limited team growth opportunities.
unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Under Fasting Condition
Bioequivalence Study of Fluoxetine Hydrochloride Delayed-Release Capsules 90 mg of Dr. Reddy's Under Fed Condition
90 mg Fluoxetine Hydrochloride Capsules Under Fasting Conditions
90 mg Fluoxetine Hydrochloride Capsules Under Non-Fasting Conditions
To Demonstrate the Relative Bioavailability of Fluoxetine Hydrochloride Capsules, 40 mg
Worked on FLUOXETINE HYDROCHLORIDE at Lavipharm? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job openings and peak lifecycle status, this product offers limited career growth opportunities and is primarily relevant for professionals focused on market defense, cost optimization, and generic transition management. Career progression on this asset is constrained by mature market dynamics and the absence of clinical or commercial expansion drivers.